

1 **BDNF, inflammatory and oxidative levels in treatment-**  
2 **naïve ADHD children treated with methylphenidate: An**  
3 **open cohort protocol.**

4  
5  
6 Marina Silva de Lucca<sup>1¶\*</sup>, Laira Lopes Tonon<sup>2&</sup>, Jordânia Alves Ferreira<sup>2&</sup>, Bárbara Silva  
7 Cabral<sup>2&</sup>, Cleuberton Kenedy Oliveira Raimundo<sup>2&</sup>, Sílvia Almeida Cardoso<sup>2¶</sup>, Débora  
8 Marques de Miranda<sup>3¶</sup>

9  
10 <sup>1</sup>Health Sciences Postgraduate Program, Faculty of Medicine, Federal University of  
11 Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

12 <sup>2</sup>Department of Medicine and Nursing, Federal University of Viçosa, Minas Gerais, Brazil.

13 <sup>3</sup>Department of Pediatrics, Faculty of Medicine, Federal University of Minas Gerais, Belo  
14 Horizonte, Minas Gerais, Brazil.

15 \* Corresponding author

16 E-mail: [marinadelucca@ufv.br](mailto:marinadelucca@ufv.br)

17  
18 ¶These authors contributed equally to this work.

19 &These authors also contributed equally to this work

20

21

22

## 23 **Abstract**

24           The attention-deficit hyperactivity disorder (ADHD) has a complex etiology,  
25 involving the interaction between biological, genetic, and environmental factors. The  
26 ADHD pathophysiology remains unknown even though there are hypotheses that  
27 inflammatory, hormonal, oxidative and neurotrophic factors are associated. This clinical  
28 trial aims to evaluate the contribution of brain derived neurotrophic factor (BDNF),  
29 inflammatory and oxidative levels before and after 12 and 24 weeks of methylphenidate  
30 use.

31

## 32 **Methods**

33           Patients will be screened upon their entry into Child and Adolescent Psychiatry  
34 Teaching Outpatient Clinic of the Medical Course at the Federal University of Viçosa in  
35 Minas Gerais, Brazil. One hundred and fifty ADHD treatment-naïve children of both sexes,  
36 between 6–14 years old, will be invited to participate, after the ADHD diagnosis by an  
37 experienced psychiatrist and the child fulfilling the inclusion criteria. Children and their  
38 caregivers will answer questionnaires regarding mental health and the children will  
39 undergo neuropsychological tests, physical, nutritional and activity assessment, in  
40 addition to blood sampling at baseline, 12 and 24 weeks of methylphenidate use  
41 respectively.

42

## 43 **Discussion**

44 This clinical trial intends to verify how the pharmacological treatment changes the  
45 plasma BDNF, inflammatory and oxidative levels in treatment-naïve Brazilian children  
46 diagnosed for ADHD.

47

## 48 **Trial Registration**

49 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).

50 Trial identifier: 13612

51 Registry name: Níveis de neurotrofina, perfil inflamatório e oxidativo em crianças com  
52 TDAH tratadas com metilfenidato.

53

## 54 **Administrative information – Spirit 2013 Checklist**

### 55 **Title {1}**

56 BDNF, inflammatory and oxidative levels in treatment-naïve ADHD children treated with  
57 methylphenidate: An open cohort protocol.

58

### 59 **Trial registration**

#### 60 **Registry {2a}**

61 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).

62 Trial identifier: 13612.

63 Registry name: Neurotrophin level, inflammatory and oxidative profile in ADHD children  
64 treated with methylphenidate.

65

## 66 **Data Set {2b}**

67 The Universal Trial Number (UTN) is U1111-1285-2908.

68 Date recruitment began: 23/10/2020; Approximate date when recruitment will be  
69 completed: 29/11/2022.

70

## 71 **Protocol version {3}**

72 First version.

73 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).

74 Trial identifier: 13612.

75

## 76 **Funding {4}**

77 National Council for Scientific and Technological Development (CNPQ).

78 Research Support Foundation of the State of Minas Gerais (FAPEMIG - APQ-01023/18)

79

## 80 **Roles and Responsibilities {5}**

### 81 **Contributorship {5a}**

82 Marina Silva de Lucca. Master in Physical Education and PhD student in Health Sciences,  
83 Faculty of Medicine, UFMG.

84 Laira Lopes Tonon. Medicine student (UFV). Research volunteer member.

85 Bárbara Silva Cabral. Medicine student (UFV). Research volunteer member.

86 Jordânia Alves Ferreira. Medicine student (UFV). Scientific initiation scholarship  
87 Cleuberton Kenedy Oliveira Raimundo. Medicine student (UFV). Research volunteer  
88 member.  
89 Silvia Almeida Cardoso. Master and Doctor in Immunology (USP). Associate Professor  
90 of Nursing and Medicine, Faculty of Medicine, UFV.  
91 Débora Marques de Miranda. Master and Doctor in Biochemical and Molecular  
92 Pharmacology (UFMG). Associate Professor of Pediatrics, Faculty of Medicine, UFMG.  
93 ML is the Chief Investigator; she conceived the study, led the proposal and protocol  
94 development. LLT, BSC, JAF and CKOR contributed to development of the proposal and  
95 methodology. SC e DM contributed to study design and to development of the proposal  
96 and methodology. All authors read and approved the final manuscript.

97

## 98 **Sponsor contact information {5b}**

99 Not applicable.

100

## 101 **Sponsor and Funder {5c}**

102 This funding source had no role in the design of this study and will not have any role  
103 during its execution, analyses, interpretation of the data, or decision to submit results.

104

## 105 **Committees {5d}**

## 106 **Principal Investigator and Research Physician**

107 Design and conduct the clinical appointments: Marina Silva de Lucca.

108 Preparation of protocol and revisions: Marina Silva de Lucca, Sílvia Almeida Cardoso,  
109 and Débora Marques de Miranda.

110 Organizing steering committee meetings: Marina Silva de Lucca and Débora Marques de  
111 Miranda.

112 Publication of study reports: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora  
113 Marques de Miranda.

114

## 115 **Steering committee**

116 The composition of the trial committee includes all authors.

117 Agreement of final protocol: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora  
118 Marques de Miranda.

119 All lead investigators will be steering committee members.

120 Recruitment of patients: Laira Lopes Tonon, Bárbara Silva Cabral and Jordânia Alves  
121 Ferreira, Cleuberton Kenedy Oliveira Raimundo.

122 Reviewing progress of study and if necessary, agreeing changes to the protocol and/or  
123 investigators brochure to facilitate the smooth running of the study: Marina Silva de Lucca  
124 and Débora Marques de Miranda.

125

## 126 **Trial Management Committee (TMC)**

127 Study planning; Organization of steering committee meetings: Marina Silva de Lucca and  
128 Débora Marques de Miranda.

129 Data verification: Marina Silva de Lucca.

130 Endpoint adjudication: Marina Silva de Lucca and Débora Marques de Miranda.

131

## 132 **Data Management team**

133 Data entry, data verification: Laira Lopes Tonon, Bárbara Silva Cabral, Jordânia Alves

134 Ferreira, Cleuberton Kenedy Oliveira Raimundo and Marina Silva de Lucca.

135

## 136 **Lead Investigators**

137 Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora Marques de Miranda.

138

## 139 **Schedule of enrolment, interventions, and** 140 **assessments**

141

## 142 **Introduction**

143

## 144 **Background and rationale {6a}**

145 Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder  
146 characterized by symptoms of inattention, hyperactivity, and impulsivity that appear in  
147 childhood and usually persist into adulthood, causing some degree of dysfunction in daily

148 activities [1,2,3]. The heterogeneous clinical presentations of ADHD are a hallmark of this  
149 disorder [4] important negative outcomes are reported, both in terms of morbidity and  
150 mortality [3].

151 ADHD has a complex etiology, involving the interaction between genetic, biological  
152 and environmental factors. However, its pathophysiology remains unknown [5]. There are  
153 hypotheses that inflammatory, oxidative, hormonal, and neurotrophic factors are  
154 associated, and they have mutual interactions. [3,6].

155 Different ADHD risk factors, such as prematurity, paternal smoking, exposure to  
156 pesticides and lead may be associated with common pathophysiological pathways, such  
157 as inflammation, oxidative stress, and neurotrophic factors. Likewise, intrauterine pro-  
158 inflammatory factors during the gestational period may be associated with restricted  
159 intrauterine growth, miscarriage, premature birth, placenta abruption, neurological  
160 damage, some of which are risk factors for ADHD [7,8,9, 10, 11, 12]. Neuroinflammation  
161 in physiological and pathological conditions may activate microglia, astrocytes,  
162 oligodendrocytes, and ependymal cells. In addition, it may increase proteases, glutamate,  
163 reactive oxygen species, nitric oxide, chemokines, toxic cytokines, prostaglandins, and  
164 may induces infiltration of T and B neutrophils, monocytes/ macrophages and dendritic  
165 cells. When activated, these cells release pro-inflammatory cytokines that increase  
166 neuroinflammation [13]. Some cytokines are elevated in ADHD, some of which are related  
167 to the severity of symptoms [13, 14, 15]. A systematic review on the level of cytokines in  
168 peripheral blood showed increased levels of cytokines-interleukin-6 (IL-6) in patients with  
169 ADHD, especially in those younger than eighteen years and not on medication, when  
170 compared to a healthy control group [13, 16]. However, another systematic review found



171 no difference in IL-6 levels when comparing children with and without ADHD [17].  
172 Furthermore, patients with ADHD, especially in those younger than eighteen years and  
173 not on medication, had lower levels of tumor necrosis factor-alpha human (TNF-alpha)  
174 compared to healthy controls [16, 17]. The results regarding cytokines-interleukin-10 (IL-  
175 10) were contradictory and may be increased or unchanged in children with ADHD  
176 compared to children without the pathology [13, 16, 17]. ADHD treated patients seem to  
177 have a decrease in interferon gamma (IFN-gamma) and interleukin-13 (IL-13) levels,  
178 compared to those naïve to treatment [13].

179 Therefore, neuroinflammation could alter the blood-brain barrier, neurotransmitter  
180 metabolism, increase oxidative stress, and neurodegeneration [14, 15]. Animals and  
181 humans with ADHD show, in different brain structures, an increase in reactive oxygen  
182 species without an adequate antioxidant response, resulting in an increase in oxidative  
183 stress. This negative imbalance in ADHD may be explained in the central nervous system  
184 due to the large consumption of oxygen by neurons associated with an antioxidant  
185 defense system of modest action and a constitution rich in lipids. As a result, the brain  
186 has difficulty regulating excess reactive oxygen species, making it more susceptible to  
187 damage [15, 18, 19, 20, 21, 22]. Therefore, there is evidence of increased oxidative stress  
188 in ADHD patients [19, 20, 21 22, 23, 24].

189 ADHD may be associated with a decrease in ascorbate, catalase, albumin and  
190 bilirubin and an increase in uric acid. So, it may contribute to oxidative stress increase  
191 [25]. On the other hand, treatment with methylphenidate seems to increase catalase  
192 levels. Other study demonstrated that the activity of superoxide dismutase (SOD), an  
193 important antioxidant defense enzyme, is lower in patients with ADHD [25].

194 Increased oxidative stress may be associated with reduced levels of BDNF, as well  
195 as reduced oxidative stress with increased BDNF [26]. Therefore, changes in the BDNF  
196 expression at critical moments during development may promote a cascade of events  
197 interfering with the brain maturation of some regions, being a substrate for altered  
198 response to stress in adulthood and development of neuropsychiatric disorders [26].  
199 Another evidence of intense oxidative stress is the modulation of telomere size and  
200 shortening during life [27] and telomere shortening is present in ADHD children [28]. So,  
201 telomere length may be a potential biomarker of the ADHD symptoms burden in families  
202 affected by this neurodevelopmental disorder [29].

203 Studies with rats have been trying to observe the results of chronic use of  
204 methylphenidate in brain cells [30, 31, 32]. Chronic use of methylphenidate in healthy rats  
205 caused oxidative damage in the brain of young rats [30]. Furthermore, the chronic use of  
206 methylphenidate by adult rats induced oxidative stress and inflammation in the  
207 hippocampus, causing cellular damage in this area [31]. Increased oxidative stress was  
208 also observed in spontaneously hypertensive adult rats (animal version of ADHD) [32].

209 In ADHD children and adolescents' study, low levels of nitric oxide were found in  
210 baseline, which did not change significantly with the use of methylphenidate over ten  
211 weeks [33]. Guney et al. (2015) [33] found that methylphenidate may reduce oxidant  
212 levels and increase antioxidant levels in children and adolescents.

213 Studies have evaluated BDNF levels in individuals with ADHD, comparing them  
214 with typical children [17, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51]  
215 and after stimulant treatment [40, 45, 50, 51, 52], with divergent results.

216 Due to the controversial studies and the importance of treating ADHD, this protocol  
217 study aims to explain the methodology that will evaluate BDNF, inflammatory and  
218 oxidative levels, their associated factors in ADHD treated children for 6 months with  
219 methylphenidate.

220

## 221 **Choice of comparators {6b}**

222 BDNF, inflammatory markers and oxidative stress levels of the ADHD children will  
223 be compared before and after methylphenidate use. Therefore, the same group of  
224 children will be compared in three different times: before starting methylphenidate and  
225 after 12 and 24 weeks of methylphenidate use. All patients will be in follow-up at the child  
226 and adolescent psychiatry outpatient clinic, receiving pharmacological treatment for  
227 ADHD. Local health system provides free methylphenidate (generic medication) in the  
228 presentation of 10mg, immediate-release tablets.

229 Control groups (ADHD children without methylphenidate use) will not be  
230 possible, because it would be unethical to deprive them of effective treatment, capable of  
231 reducing not only morbidity, but also mortality.

232

## 233 **Objectives {7}**

234 The objectives of this open cohort clinical trial will be:

- 235 1. Evaluate the BDNF, inflammatory and oxidative levels before and after 12 and 24  
236 weeks of methylphenidate use in treatment-naïve ADHD children.

237 2. Investigate if there is a moderating effect of the sociodemographic data, ADHD  
238 presentation, comorbidity presence, caregiver psychopathology, parenting styles,  
239 emotional regulation level on BDNF, cytokines and oxidative stress level, telomere  
240 length, and other variables from the survey instruments detailed throughout this  
241 protocol.

242

## 243 **Trial Design {8}**

244 This trial is designed as an open cohort, single center, with convenience sample.

245

## 246 **Methods: Participants, Interventions, Outcomes**

### 247 **Study setting {9}**

248 All subjects will be invited to the child psychiatry teaching outpatient clinic at the  
249 Federal University of Viçosa (UFV), in the state of Minas Gerais, Brazil.

250

### 251 **Eligibility criteria {10}**

#### 252 **Participants inclusion criteria: {10}**

253 Treatment-naïve ADHD children, of both sex in outpatient treatment; age  
254 between complete 6 and incomplete 15 years old. Children must have criteria for ADHD  
255 diagnosis according to the DSM-5 and must not have chronic diseases or use of any other  
256 medications that may interfere with the immune system or BDNF. Children who need iron  
257 or vitamin replacement may be included. The following comorbidities may be included:

258 oppositional defiant disorder (ODD), tic disorder, enuresis, encopresis, skin picking  
259 disorder. Autism spectrum disorder (ASD) level 1, Classification of Diseases and Related  
260 Health Problems (ICD) 10 F84.5, could be included if the diagnosis occurs during the  
261 study. All parents must sign the free and informed consent form, just like children should  
262 also sign the assent form. The terms will be delivered during the initial assessment of the  
263 participants, if they wish to participate voluntarily in the research.

264

## 265 **Participants exclusion criteria: {10}**

266 Families and children that refusal to participate in the research or refusal to use  
267 stimulant medications; presence of autoimmune, neurodegenerative diseases, and  
268 immunodeficiencies; intellectual disability, severe clinical or psychiatric comorbidities,  
269 except autism spectrum disorder level 1 (ICD 10 F84.5), ODD, tics, trichotillomania, skin  
270 picking disorder, enuresis, and encopresis; previous or current use of stimulants or other  
271 psychiatry medications; current use of medications for chronic diseases or that interfere  
272 in immune system or BDNF levels (antidepressants for example); girls who have  
273 menstruated; stimulant contraindication use.

274

## 275 **Participant timeline: {13, 14, 15, 18}**

276 Participants will be included from October 2020 to November 2022, targeting a  
277 sample size of 150 children, based on sample calculation with analysis power between  
278 80% and 95% of accuracy. This sample calculation was based on an article of Akay et  
279 al., 2017 [37].

280 They will be forwarded by physicians, schools and psychologists from the city  
281 and health region. To reach the sample number, the health units, as well as the municipal  
282 education department were communicated about the research and how the children could  
283 be referred for screening. There was also publicity on the local radio and the website of  
284 the Federal University of Viçosa.

285 Children who are eligible for the study will be categorized by ADHD presentation,  
286 disorder severity, with or without Oppositional Defiant Disorder (ODD), with or without  
287 autism spectrum disorder (ASD), at any emotional dysregulation level. Their caregivers  
288 will be sorted by parenting style.

289 Overall, each participant will make 8 to 10 visits during the study period.

290 The research procedure for participants at each visit are described in Fig. 2.

291 The initial assessment includes the semi-structured interview Kiddie-Schedule  
292 for Affective Disorders and Schizophrenia – Present and Lifetime Version (K-Sads-PL  
293 2013) [53].

294 To assess the severity of ADHD symptoms, the SNAP-IV scale, Swanson, Nolan  
295 e Pelham version [54], and the Assessment Scale of Childhood and Adolescent  
296 Behaviors in ADHD in a Family Environment (ETDAH-parents) [55] and ADHD Self-  
297 Assessment Scale-Version for Children and Adolescents (ETDAH-Criad) [56] were  
298 answered by parents and children. The SNAP-IV scale has 26 items, which also  
299 investigates symptoms of a common comorbidity that is Defiant and Oppositional  
300 Disorder. [54]. The ETDAH scale has one version for parents and another for the children.  
301 [55,56]. The parent subscale has four subscales that investigates symptoms of  
302 inattention, hyperactivity/impulsivity, emotional regulation, and adaptive behavior. The

303 children subscale has 2 subscales that investigates inattention and  
304 hyperactivity/impulsivity symptoms.

305 The diagnosis will be confirmed by an interview done by a Child and Adolescent  
306 Psychiatrist. Sociodemographic data was obtained from the Brazil Economic Ranking  
307 Criterion and “Background information” part of the K-Sads-PL instrument (K-Sads-PL  
308 2013) [53, 57, 58]. A standard record for the clinical history was constructed with data on  
309 pregnancy, childbirth, neuropsychomotor development, and the child's previous and  
310 family history.

311 For the care of children at the outpatient clinic, an anamnesis model was built.  
312 This anamnesis also includes a habitual physical activity questionnaire [59], Brazilian food  
313 safety scale [60], SISVAN food consumption markers questionnaire [61], food frequency  
314 questionnaire [62, 63], bullying questionnaire (Kidscape) [64], measurement  
315 questionnaire adherence to treatment [65], CRAFFT/CESARE instrument (Car; Relax;  
316 Alone; Forget; Family/Friends; Trouble acronym) [66].

317 Situations of violence and/or health identified during the research will be duly  
318 forwarded to the necessary assistance network, such as justice, other medical specialties,  
319 social services, and others. The caregiver is screened for symptoms of depression,  
320 anxiety, ADHD, and alcohol use [67, 68, 69, 70]. In case of positive screening, evaluation  
321 by an adult psychiatrist will be offered.

322

## 323 **Interventions {11a, 18}**

### 324 **Screening visits**

325 Medical students trained by an experienced child and adolescent psychiatrist  
326 and under her supervision, will apply in the first assessment (between one and three  
327 visits): Fig. 1. Schedule of enrolment, interventions, and assessments.

328 # Multimodal Treatment Assessment Study – Swanson, Nolan e Pelham (MTA-  
329 SNAP-IV) scale, that evaluates symptoms of attention deficit/hyperactivity disorder  
330 and oppositional defiant disorder in children and adolescents [54]

331 # Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged  
332 Children – Lifetime Version (K-Sads-PL 2013) [53]

333 # Sociodemographic questionnaire, including the Brazil Economic Ranking Criterion  
334 and the background information of the K-Sads-PL 2013 [53,57,58]

335 # ADHD Behavior Assessment Scale – Parents Version (ETDAH-parents) [55]

336 # Bullying questionnaire [64]

337 # Physical activity questionnaire [59]

338 # SISVAN food consumption markers [61]

339 # Brazilian Food Security Scale (EBIA) [60]

340 # Scale of Sleep disorders in children [72]

341 # Behavior Inventory for Children and Adolescents (CABI) [73]

342 # Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ) [74]

343 # Epidemiological Studies Center Depression Scale (CES-D) [67]

344 # State-Trait Anxiety Inventory (IDATE) [68]

345 # Adult Self-Report Scale (ASRS-18) [69]

346 # Alcohol Use disorders identification test (AUDIT) [70]

347 # Standardized psychiatric clinic interview with standard record.



348 # Physical examination.

349

350 Psychology students, under supervision of an experienced psychologist in  
351 neuropsychology will apply:

352 # Scale for screening drug use CRAFFT/CESARE [66]

353 # Social Skills Test for Children and Adolescents in School Situation (THAS-C) [75]

354 # ADHD Self-Assessment Scale – Version for Children and Adolescents (ETDAH-  
355 CriAd) [56]

356 # Standardized and validated psychological tests for the Brazilian population.

357 • Non-Verbal test of Children's Reasoning (TNVRI) [76]

358 • Battery for Attention Assessment (BPA) [77, 78]

359 • Five digits teste (FDT) [79]

360 • Brief Child Neuropsychological Assessment Instrument (NEUPSILIN-inf)  
361 [80]

362

363 Nutrition's student under supervision of an experienced nutritionist will apply:

364 # 24-hour food recall [81, 82]

365

## 366 **Assessment points {11a, 18a}**

367 The assessment points occur in three timepoints: baseline (before  
368 methylphenidate initial use) and after 12 and 24 weeks of methylphenidate use. Fig 1  
369 and 2.

370 In the first assessment point the blood sample is collected, the family receives  
371 psychoeducation about the disorder and its treatment, and the methylphenidate is started.

372 In the second and third assessment points, all instruments will be applied in  
373 screening are reapplied, except K-Sads-PL, sociodemographic questionnaire,  
374 standardized psychiatric clinic interview with standard record and NEUPSILIN-inf. In  
375 these two timepoints, we will use standardized follow-up anamnesis. Participants will also  
376 be clinically evaluated to verify the effect of the treatment (the Clinical Global Impressions  
377 (CGI) scale) [83, 84, 85], dose adjustment, the presence of adverse effects, adherence  
378 to treatment, clarification of doubts regarding the research, the disorder, and the  
379 treatment and reinforce the guidelines regarding the next steps of the study.

380

## 381 **Follow-up visits {11a, 18a}**

382 Participants will also be clinically evaluated at 4, 8 and 18 weeks to verify the  
383 effect of the treatment, dose adjustment, the presence of adverse effects, adherence to  
384 treatment, clarification of doubts regarding the research, the disorder, the treatment and  
385 reinforce the guidelines regarding the next steps of the study.

386 The number of visits could vary, depending on the patient's individual needs.

## 387 **Pharmacotherapy {11b}**

388 Pharmacotherapy will be conducted by experienced child and adolescent  
389 psychiatry with primary responsibility for childcare.

390 Pharmacotherapy starts with a first-line stimulant medication methylphenidate.  
391 [86]. The initial dose will be prescribed as follows: 5mg in the morning and after lunch in

392 the first week, with adjustment to 10mg at the same time until the next evaluation at 4  
393 weeks. From that moment on, the dose will be titrated to optimize the desired therapeutic  
394 effect and minimize undesirable adverse effects. The average dose will be 1 mg/kg/day.

395 If the child does not tolerate the methylphenidate [87, 88] or does not respond to  
396 medication, lisdexamfetamine will be offered. [88] Other formulations may be used such  
397 as methylphenidate hydrochloride extended-release capsules or OROS methylphenidate  
398 if necessary. In these cases, equivalent doses will be prescribed.

399

## 400 **Blood sample {11a}**

401 A trained nursing professional will collect three samples of venous blood from  
402 each patient/volunteer: before medication treatment, 12 and 24 weeks after starting  
403 treatment. Blood samples will be kept at a suitable temperature [89] until they are sent to  
404 the Biochemistry laboratory of the Department of Biochemistry (UFV). The BDNF [90] and  
405 the cytokines levels [91, 92, 93, 94] will be evaluated in blood plasma and the oxidative  
406 stress [95,96] level will be evaluated in serum. Telomeres measurements will be made by  
407 DNA extraction [27, 28, 29].

408

## 409 **Adherence to intervention protocols {11c, 18b}**

410 To improve adherence to medical visits and research evaluations, nursing  
411 technique will confirm the consultation by telephone (calls or WhatsApp messages) the  
412 day before. In case of participant absence, contact by phone will be made to offer  
413 appointment rescheduling.

414 The assessment methylphenidate adherence will be by pill count and the  
415 Treatment Adherence Measure (MAT) questionnaire [65] in all scheduled visits [97].

416

## 417 **Modifications {11b}**

418 The participant will be excluded from the survey if he does not attend the  
419 assessment points (blood collection times). If the patient reports the impossibility of  
420 attending the assessment visit and is available to reschedule it within a maximum of 15  
421 days, the patient can proceed with the intervention. The patient may miss the visits  
422 number 4, 8, 18 and proceed with the intervention, if the regular use of medication  
423 continues.

424 The child will be excluded in case of not tolerating the medication, family  
425 withdraws from participation, diagnosis change during follow-up.

426 The pharmacological intervention may have adverse effects and the child will  
427 receive all the necessary and standard care following strictly the clinical protocol. Most  
428 adverse effects are usually mild and occur early in treatment [87]. They will be informed  
429 and medication will be adjusted accordingly the need.

430 Participants whose diagnosis on screening differs from the diagnosis of the  
431 psychiatry team will be excluded from the study.

432

## 433 **Concomitant care {11d}**

434 The treatment can also include speech therapy and occupational therapy if there  
435 is a clinical indication. The psych treatment was not available.

436

## 437 **Outcomes {12}**

### 438 **Primary outcomes:**

439 The BDNF levels [37], cytokines and level of oxidative stress (oxidative and  
440 antioxidant substances) after treatment with methylphenidate.

441

### 442 **Secondary outcomes:**

443 Behavioral symptoms of Attention Deficit/Hyperactivity Disorder and/or  
444 Oppositional Defiant Disorder, emotional regulation level determined by the Multimodal  
445 Treatment Assessment Study - Swanson, Nolan e Pelham (MTA-SNAP-IV) scale, which  
446 assesses symptoms of attention deficit/hyperactivity disorder and Oppositional Defiant  
447 Disorder in children and adolescents, and ETDAH - parents, which assesses emotional  
448 regulation.

449 Cardiovascular parameters on physical examination, as well as body mass index  
450 will be recorded.

451

## 452 **Retention {18b}**

453 The intervention has the potential to bring great benefits to the child and whole  
454 family. The stimulant treatment in ADHD children is associated with reduced morbidity  
455 and mortality.

456 WhatsApp contact will be possible for participants to clarify their doubts,  
457 reschedule the appointment, as well as be reminded of the appointments during the  
458 period in which they participate in the study.

459 Moreover, a report containing the child's neuropsychological assessment will be  
460 given to the parents. In addition, all children will be under medical supervision at the  
461 outpatient clinic, even after the end of the study (UFV).

462 Post-intervention measures will not be necessary after the twenty-fourth week.  
463 The analysis will be performed with the information obtained up to the time of dropping  
464 out in case of child drops out of the study.

465

## 466 **Data Management {19}**

467 A part of the data will be entered electronically and registered in REDCap  
468 database. A random sampling checking will be done to quality control.

469 Participant research files are attached to their medical records, so they will be  
470 kept for 20 years after the last registration.

471

## 472 **Statistical Methods {20}**

### 473 **Outcomes {20a}**

474 The main analysis strategies will involve group comparison from the three  
475 timepoints and trajectory of symptoms and measures across time. Generalized  
476 Estimating Equations (GEE) analyses may be done with risk factors and potential

477 moderators such social deprivation, parental styles, and oppositional symptoms to  
478 understand the relationship.

479

## 480 **Additional analyses {20b}**

481 The main additional analyses strategies will involve descriptive data to  
482 characterize the studied sample and to observe the correlations between features.

483

## 484 **Analysis Population and Missing Data {20c}**

485 Individuals that will not fill the information of the primary outcomes will have the  
486 other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative  
487 stress at baseline to understand potential populational bias.

488 Missing data will be handled as necessary for the chosen tests, for GEE for  
489 example we will include only individuals with the complete data set for primary outcomes.  
490 We will try to retrieve all information by WhatsApp contact.

491

492

## 493 **Methods: Monitoring**

### 494 **Data Monitoring {21}**

#### 495 **Formal Committee {21a}**

496           Diagnosis data was done by thirteen years experienced child psychiatry and there  
497 is a team on UFMG to discuss any doubt prof. DMM and AASJ. They also have 15 years  
498 of experience in the field.

499

## 500 **Interim Analyses {21b}**

501           Individuals that will not fill the information of the primary outcomes will have the  
502 other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative  
503 stress at baseline.

504           Socioeconomic data will be analyzed to evaluate any potential of sampling bias.

505           The clinical psychiatric assessment will be done by an experienced child and  
506 adolescent psychiatry, and any diagnosis divergence will be informed. Adherence will be  
507 considered poor if the child takes less than 2/3 of prescribed doses of methylphenidate.

508

## 509 **Harms {22}**

510           Adverse events during the trial will be registered in the child's medical record and  
511 communicated to the relevant governmental agencies if necessary.

512           Assistance in case of adverse events will be guaranteed to the child via the public  
513 health system.

514

## 515 **Auditing {23}**

516           All data will be available to audit if necessary. The diagnosis divergence will be  
517 evaluated and informed as soon as it is verified.



518

## 519 **Ethics and Dissemination**

### 520 **Research Ethics Approval {24}**

521           Approved by the Research Ethics Committee of the Federal University of Minas  
522 Gerais. Number: 4.364.744. CAAE: 82870117.0.3001.5149. Written, informed consent  
523 to participate will be obtained from all parents, as well as informed assent from the  
524 children.

525

### 526 **Protocol Amendments {25}**

527           Any modifications to the protocol which may impact on the conduct of the study,  
528 potential benefit of the patient or may affect patient safety, will lead to a formal  
529 amendment to the protocol with REBEC, the ethics committee and clinical trial publication  
530 journal.

531

### 532 **Consent or Assent {26}**

#### 533 **Consent or Assent {26a}**

534 All parents must sign the free and informed consent form, as well as the children the  
535 assent form. The terms will be delivered at the end of the child's screening if the child is  
536 considered eligible to be included in the study and they wish to participate voluntarily in  
537 the research.

538

## 539 **Ancillary Studies {26b}**

540 Not Applicable

541

## 542 **Confidentiality {27}**

543 All study-related information will be stored securely at the child's medical record.

544 All local databases will be secured with password-protected access systems.

545

## 546 **Declaration of Interests {28}**

547 The author(s) declare(s) that they have no competing interests.

548

## 549 **Access to Data {29}**

550 All researchers will have access to the final trial dataset without any contractual  
551 limitations.

552

## 553 **Ancillary and Post-trial Care {30}**

554 The children will continue clinical treatment at the child psychiatry outpatient  
555 clinic for as long as the family wishes, or they will be discharged or reach the age of 18,  
556 when they will be referred to adult services.

557

## 558 **Dissemination Policy {31}**

## 559 **Trial Results {31a}**

560 All research data and personal information will be under responsibility of the  
561 researchers to protect confidentiality before, during and after the trial. All parents or  
562 guardians' results will be communicated at the end and regarding the trial results.

563 Trial results will be published at REBEC, regardless of the magnitude or direction  
564 of effect. The results will also be reported in an original article and submitted for a relevant  
565 journal.

566

## 567 **Authorship {31b}**

568 ML is the Chief Investigator; she conceived the study, led the proposal and protocol  
569 development. L, B and J contributed to development of the proposal and methodology.  
570 SC e DMM contributed to study design and to development of the proposal and  
571 methodology. All authors will read and approve the final manuscript.

572

## 573 **Reproducible Research {31c}**

574 The anonymous data information might be available under request and reasonable  
575 demand.

576

## 577 **Discussion**

578 Inflammatory, neurotrophic, and oxidative parameters have been associated with  
579 the pathophysiology of ADHD. Limitations in the studies varies from small and

580 heterogeneous samples of participants [12], lack of control for variables that may interfere  
581 with the results, such as diet, body mass index, short follow-up time, and level of physical  
582 activity, are some of these limitations. Moreover, the results are contradictory [98]. Here  
583 we propose a protocol trying to make clear clinical and biomarkers in response to  
584 medication in a cohort well characterized in a prospective follow up.

585 Many studies were cross-sectional and retrospective, which allows inferring only  
586 an association between inflammation and the disorder and not a causal relationship of  
587 pathogenesis [98]. Longitudinal studies are necessary to better establish the possible  
588 relationship between ADHD, inflammation, neurotrophic, and oxidative stress [16]. Other  
589 important factors to be considered are comorbid mental disorders and potential  
590 confounding factors, in addition to being important to observe possible changes in the  
591 inflammatory profile after interventions [16].

592 This trial protocol methodology will follow the participants by 24 weeks, increasing  
593 the chance of evaluating the influence of the chronic use of methylphenidate on  
594 inflammatory, neurotrophic, and oxidative factors. In addition, there will be evaluation of  
595 the child's diet and physical activity through the food recall and the usual physical activity  
596 questionnaire, respectively. To reduce hormonal influences of puberty, we will exclude  
597 girls who had menarche and limited the age of both sexes to 14 years.

598 The results may provide information about the pathophysiology of ADHD, being able  
599 to collaborate in the identification of biomarkers of the disorder and response to treatment  
600 with methylphenidate.

601

602

603 **Acknowledgements**

604 Acknowledgment to the entire Specialized Health Care team (UAES/UFV),  
605 Biochemistry and Medicine laboratory (UFV) team, Molecular Medicine laboratory  
606 (UFMG) team, scientific initiation students (UFV), psychology students (volunteer  
607 member/Univiçosa), nutrition professor and student (UFV), the neuropsychologist  
608 Roselaine da Cunha Barros (volunteer member), and the nursing techniques Arieta de  
609 Jesus Felisberto Oliveira (UFV) e Ana Cristine Pepe Parabocz (UFV).

610

## 611 **Appendices**

612

### 613 **Appendix 1. Informed consent materials {32}**

614

### 615 **Appendix 2. Consent and Assent forms {32}**

### 616 **Appendix 3. Biorepository constitution {32}**

617

## 618 **Biological specimens {33}**

619 Collection and analysis of biological samples will follow standard protocols for  
620 these procedures in accordance with health surveillance recommendations.

621 Biorepository term was signed and contains the norms of storage and use in  
622 auxiliary and future studies. (Appendix 3)

623

## 624 **References**

- 625 1. Biederman J, Faraone S. Attention-deficit Hyperactivity Disorder. *Lancet*. 2005;  
626 (9481):237–248.
- 627 2. Edition F. *Diagnostic and Statistical Manual of Mental Disorders*. American  
628 Psychiatric Association. 2013; 21.
- 629 3. Sharma A, Couture J. A Review of the Pathophysiology, Etiology, and Treatment  
630 of Attention-Deficit Hyperactivity Disorder (ADHD). *Annals of Pharmacotherapy*.  
631 2013 Nov;48(2):209–25.
- 632 4. Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD:  
633 Current Concepts and Treatments in Children and Adolescents. *Neuropediatrics*  
634 [Internet]. 2020 Oct 1;51(5):315–35.
- 635 5. Núñez-Jaramillo L, Herrera-Solís A, Herrera-Morales WV. ADHD: Reviewing the  
636 Causes and Evaluating Solutions. *Journal of Personalized Medicine*. 2021 Mar  
637 1;11(3):166.
- 638 6. Dursun S, Demirci E, Kilic E, Ozmen S. A Different View on the Etiopathogenesis  
639 of Attention-deficit Hyperactivity Disorder from an Inflammation Perspective.  
640 *Clinical Psychopharmacology and Neuroscience*. 2021 Feb 28;19(1):145–54.
- 641 7. Larson K, Russ SA, Kahn RS, Halfon N. Patterns of Comorbidity, Functioning, and  
642 Service Use for US Children With ADHD, 2007. *Pediatrics* [Internet]. 2011 Mar  
643 1;127(3):462–70.
- 644 8. Heyer DB, Meredith RM. Environmental toxicology: Sensitive periods of  
645 development and neurodevelopmental disorders. *NeuroToxicology*. 2017 Jan;  
646 58:23–41.

- 647 9. Sogard AS, Mickleborough TD. The therapeutic potential of exercise and caffeine  
648 on attention-deficit/hyperactivity disorder in athletes. *Frontiers in Neuroscience*.  
649 2022 Aug 12;16.
- 650 10. Lopresti AL. Oxidative and nitrosative stress in ADHD: possible causes and the  
651 potential of antioxidant-targeted therapies. *ADHD Attention Deficit and*  
652 *Hyperactivity Disorders*. 2015 Apr 19;7(4):237–47.
- 653 11. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaie A. Pesticides, and oxidative  
654 stress: a review. *Medical Science Monitor: International Medical Journal of*  
655 *Experimental and Clinical Research [Internet]*. 2004 Jun 1;10(6):RA141-147.
- 656 12. Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a risk factor for attention  
657 deficit hyperactivity disorder. *Pharmacology Biochemistry and Behavior [Internet]*.  
658 2019 Jul; 182:22–34.
- 659 13. Anand D, Colpo GD, Zeni G, Zeni CP, Teixeira AL. Attention-  
660 Deficit/Hyperactivity Disorder and Inflammation: What Does Current Knowledge  
661 Tell Us? A Systematic Review. *Front Psychiatry*. 2017; 8: 228.
- 662 14. Noakes PS, Thomas R, Lane C, Mori TA, Barden AE, Devadason SG, et al.  
663 Association of maternal smoking with increased infant oxidative stress at 3 months  
664 of age. *Thorax [Internet]*. 2007 Aug 1 [cited 2021 Aug 1];62(8):714–7.
- 665 15. Alvarez-Arellano L, González-García N, Salazar-García M, Corona JC. Antioxidants as  
666 a Potential Target against Inflammation and Oxidative Stress in Attention-  
667 Deficit/Hyperactivity Disorder. *Antioxidants*. 2020 Feb 21;9(2):176.
- 668 16. Misiak B, Wójta-Kempa M, Samochowiec J, Schiweck C, Aichholzer M, Reif A,  
669 Samochowiec A, Stańczykiewicz B. Peripheral blood inflammatory markers in

- 670 patients with attention deficit/hyperactivity disorder (ADHD): A systematic review  
671 and meta-analysis. *Progress in Neuro-Psychopharmacology Biological Psychiatry*.  
672 2022; 118.
- 673 17. Chang JP, Mondelli V, Satyanarayanan SK, Chiang YJ, Chen HT, Su KP, Pariante  
674 CM. Cortisol, inflammatory biomarkers and neurotrophins in children and  
675 adolescents with attention deficit hyperactivity disorder (ADHD) in Taiwan. *Brain*,  
676 behavior, and immunity. 2020; 88:105–113.
- 677 18. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine  
678 oxidase inhibitors. *Nature Reviews Neuroscience* [Internet]. 2006 Apr 1;7(4):295–  
679 309.
- 680 19. Leffa DT, Bellaver B, de Oliveira C, de Macedo IC, de Freitas JS, Grevet  
681 EH, Caumo W, Rohde LA, Quincozes-Santos A, Torres ILS. Increased Oxidative  
682 Parameters and Decreased Cytokine Levels in an Animal Model of  
683 AttentionDeficit/Hyperactivity Disorder. *Neurochemical research*, 2017; 42(11):  
684 30843092. DOI: 10.1007/s11064-017-2341-6.
- 685 20. Annelies V, Harry R, Annelies B, Tess DB, Nina H. Evaluation of Biomarkers of  
686 Oxidative Stress in Attention-Deficit/ Hyperactivity Disorder (ADHD). *Journal of*  
687 *Molecular Biomarkers & Diagnosis*. 2018;09(03).
- 688 21. Joseph N, Zhang-James Y, Perl A, Faraone SV. Oxidative Stress and ADHD.  
689 *Journal of Attention Disorders*. 2013 Nov 14;19(11):915–24.
- 690 22. Sezen H, Kandemir H, Savik E, Basmacı Kandemir S, Kilicaslan F, Bilinc H, et al.  
691 Increased oxidative stress in children with attention deficit hyperactivity disorder.  
692 *Redox Report*. 2016 Feb 18;21(6):248–53.



- 693 23. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-  
694 Quiroga JA, et al. Attention-deficit/hyperactivity disorder. *Nature Reviews Disease*  
695 *Primers* [Internet]. 2015 Aug 6; 1:15020.
- 696 24. Wynchank D, Bijlenga D, Beekman AT, Kooij JJS, Penninx BW. Adult Attention-  
697 Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature.  
698 *Current Psychiatry Reports*. 2017 Oct 30;19(12).
- 699 25. Lu Z, Pu C, Zhang Y, Sun Y, Liao Y, Kang Z, et al. Oxidative Stress and Psychiatric  
700 Disorders: Evidence from the Bidirectional Mendelian Randomization Study.  
701 *Antioxidants*. 2022; 11:1386.
- 702 26. Asghari A, Hosseini M, Beheshti F, Shafei MN, Mehri S. Inducible nitric oxide inhibitor  
703 aminoguanidine, ameliorated oxidative stress, interleukin-6 concentration, and  
704 improved brain-derived neurotrophic factor in the brain tissues of neonates born from  
705 titanium dioxide nanoparticles exposed rats. *The Journal of Maternal-Fetal &*  
706 *Neonatal Medicine*. 2018 Jun 17;32(23):3962–73.
- 707 27. Drury SS, Theall K, Gleason MM, Smyke AT, De Vivo I, Wong JY et al. Telomere  
708 length and early severe social deprivation: linking early adversity and cellular  
709 aging. *Molecular Psychiatry*. 2012; 17(7): 719-27.
- 710 28. Pham C, Vryer R, O'Hely M, Mansell T, Burgner D, Collier F et al., On Behalf of  
711 The Barwon Infant Study Investigator Group. Shortened Infant Telomere Length Is  
712 Associated with Attention Deficit/Hyperactivity Disorder Symptoms in Children at  
713 Age Two Years: A Birth Cohort Study. *International Journal of Molecular Sciences*.  
714 2022; 23(9): 4601.

- 715 29. Costa DS, Rosa DV, Barros AG, Romano-Silva MA, Malloy-Diniz LF, Mattos P et  
716 al. Telomere length is highly inherited and associated with hyperactivity-impulsivity  
717 in children with attention deficit/hyperactivity disorder. *Frontiers in Molecular*  
718 *Neuroscience*. 2015; 8: 28.
- 719 30. Martins M, Reinke A, Petronilho F, Gomes K, Dal-Pizzol F, Quevedo J.  
720 Methylphenidate treatment induces oxidative stress in young rat brain. *Brain*  
721 *research*. 2006; 1078: 189-197.
- 722 31. Motaghinejad M, Montevalian M, Shabab B. Effects of chronic treatment with  
723 methylphenidate on oxidative stress and inflammation in hippocampus of adult  
724 rats. *Neuroscience letters*. 2016; 619: 106-113.
- 725 32. Comim CM, Gomes KM, Réus GZ, Petronilho F, Ferreira GK, Streck EL,  
726 Dal-Pizzol F, Quevedo J. Methylphenidate treatment causes oxidative stress and  
727 alters energetic metabolism in an animal model of attention-deficit hyperactivity  
728 disorder. *Acta Neuropsychiatrica*. Cambridge University Press. 2014; 26(2): 96-  
729 103.
- 730 33. Doneray E, Yazici KU, Yazici IP, Ustundag B. Altered Arginine/Nitric Oxide  
731 Pathway in Children Diagnosed Attention Deficit Hyperactivity Disorder, and the  
732 Effect of 10 Weeks Methylphenidate Treatment. *Clinical Psychopharmacology and*  
733 *Neuroscience*. 2022; 20(2): 350-363.
- 734 34. Guney E, Cetin FH, Alisik M, Tunca H, Tas Torun Y, Iseri E, et al. Attention Deficit  
735 Hyperactivity Disorder and oxidative stress: A short term follow up study.  
736 *Psychiatry Research*. 2015 Sep;229(1-2):310–7.

- 737 35. Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, Kim YK. Increased  
738 levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention  
739 deficit-hyperactivity disorder (ADHD). *Progress in NeuroPsychopharmacology and*  
740 *Biological Psychiatry*. 2008; 32(8):1824–1828.
- 741 36. Sayyah, H. BDNF plasma level in ADHD children: correlation to different  
742 symptomatology. *Curr Psychiatry [Egypt]*, 2009; 16, 284-294.
- 743 37. Sargin E, Akay AP, Resmi H, Cengizhan SA, Ozek H, Ellidokuz H, Miral S, Orcin  
744 E. Evaluation of Serum Brain-Derived Neurotrophic Factor Levels in Children with  
745 Attention Deficit Hyperactivity Disorder: Preliminary Data. *Archives of*  
746 *Neuropsychiatry*. 2012; 49(2): 96+.
- 747 38. Scassellati C, Zanardini R, Tiberti A, Pezzani M, Valenti V, Effedri P, Filippini E,  
748 Conte S, Ottolini A, Gennarelli M, Bocchio-Chiavetto L. Serum brain-derived  
749 neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder  
750 (ADHD). *European child & adolescent psychiatry*. 2013; 23(3): 173-177.
- 751 39. Liu L, Li H, Wang Y, Yang L, Qian Q, Wang Y. Association between GUC2C and ADHD:  
752 evidence from both categorical and quantitative traits. *Psychiatry Research [Internet]*.  
753 2014 Dec 15 [cited 2023 Feb 12];220(1-2):708–10.
- 754 40. Sahin S, Yuce M, Alacam H, Karabekiroglu K, Say GN, Salis O. Effect of  
755 methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin,  
756 and brain-derived neurotrophic factor in children and adolescents with attention  
757 deficit and hyperactivity disorder. *International journal of psychiatry in clinical*  
758 *practice*. 2014; 18(4): 280–287.

- 759 41. Saadat F, Kosha M, Amiry A, Torabi G. Brain-Derived Neurotrophic Factor as a  
760 Biomarker in Children with Attention Deficit-Hyperactivity Disorder. Journal of  
761 Krishna Institute of Medical Sciences University. 2015; 4(4): 10-17.
- 762 42. Imşek Ş, Gençoğlan S, Yüksel T, Kaplan İ, Aktaş H, Alaca R. Evaluation of the  
763 Relationship between Brain-Derived Neurotrophic Factor Levels, and the Stroop  
764 Interference Effect in Children with Attention-Deficit Hyperactivity Disorder. *Noro*  
765 *Psikiyatri Arsivi*. 2016; 53(4): 348–352.
- 766 43. Bilgiç A, Toker A, Işık Ü, Kılınç İ. Serum brain-derived neurotrophic factor, glial-  
767 derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in  
768 children with attention-deficit/hyperactivity disorder. *European child & adolescent*  
769 *psychiatry*. 2017; 26(3): 355–363.
- 770 44. Reda M, El-Nady HG, Rabie MA, Fawzy R, Adel S, AwadAllah E, Moneim MA.  
771 Comparing brain-derived neurotrophic factor levels, intelligence, and memory in  
772 clinical subtypes of attention-deficit hyperactivity disorder. *Middle East Current*  
773 *Psychiatry*. 2016; 23(2): 56-62.
- 774 45. Cubero-Millán I, Ruiz-Ramos MJ, Molina-Carballo A, Martínez-Serrano S,  
775 Fernández-López L, Machado-Casas I, Tortosa-Pinto P, Ruiz-López A, LunaDel-  
776 Castillo JD, Uberos J, Muñoz-Hoyos A. BDNF concentrations and daily fluctuations  
777 differ among ADHD children and respond differently to methylphenidate with no  
778 relationship with depressive symptomatology. *Psychopharmacology*. 2016;  
779 234(2): 267–279
- 780 46. Taha H, Elsheshtawy E, Mohamed SI, Al-Azazzy O, Elsayed M, Ibrahim SAS.  
781 Correlates of brain derived neurotrophic factor in children with attention deficit

- 782           hyperactivity disorder: A case-control study. *Egyptian Journal of Psychiatry*. 2017;  
783           38(3): 159-163.
- 784           47. Wang LJ, Wu CC, Lee MJ, Chou MC, Lee SY, Chou WJ. Peripheral Brain Derived  
785           Neurotrophic Factor and Contactin-1 Levels in Patients with Attention  
786           Deficit/Hyperactivity Disorder. *Journal of clinical medicine*. 2019; 8(9):1366.
- 787           48. Yurteri N, Şahin İE, Tufan AE. Altered serum levels of vascular endothelial growth  
788           factor and glial-derived neurotrophic factor but not fibroblast growth factor2 in  
789           treatment-naive children with attention deficit/hyperactivity disorder. *Nordic journal  
790           of psychiatry*. 2019; 73(4-5): 302–307.
- 791           49. El Ghamry R, El-Sheikh M, Meguid MA, Nagib S, El Gabry DA. Plasma brain  
792           derived neurotrophic factor (BDNF) in Egyptian children with attention deficit  
793           hyperactivity disorder. *Middle East Current Psychiatry*. 2021; 28: 22.
- 794           50. Gumus C, Yazici IP, Yazici KU, Ustundag B. Increased Serum Brain-derived  
795           Neurotrophic Factor, Nerve Growth Factor, Glial-derived Neurotrophic Factor and  
796           Galanin Levels in Children with Attention Deficit Hyperactivity Disorder, and the  
797           Effect of 10 Weeks Methylphenidate Treatment. *Clinical psychopharmacology and  
798           neuroscience: the official scientific journal of the Korean College of  
799           Neuropsychopharmacology*. 2022; 20(4): 635–648.
- 800           51. Akay AP, Resmi H, Güney SA, Erkuran HÖ, Özyurt G, Sargin E, et al. Serum brain-  
801           derived neurotrophic factor levels in treatment-naïve boys with attention-  
802           deficit/hyperactivity disorder treated with methylphenidate: an 8-week,  
803           observational pretest–posttest study. *European Child & Adolescent Psychiatry*.  
804           2017 Jul 14;27(1):127–35.

- 805 52. Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, Atrkar  
806 Roushan Z. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels  
807 induced by methylphenidate in children with Attention deficit-hyperactivity disorder  
808 (ADHD). *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2013;  
809 47: 20-24.
- 810 53. Caye A, Kieling RR, Rocha TB, Graeff-Martins AS, Geyer C, Krieger F, et al.  
811 Schedule for Affective Disorders and Schizophrenia for School-Age Children –  
812 Present and Lifetime Version (K-SADS-PL), DSM-5 update: translation into  
813 Brazilian Portuguese. *Brazilian Journal of Psychiatry*. 2017 Dec;39(4):384–6.
- 814 54. Mattos P, Serra-Pinheiro MA, Rohde LA, Pinto D. A Brazilian version of the MTA-  
815 SNAP-IV for evaluation of symptoms of attention-deficit/hyperactivity disorder and  
816 oppositional-defiant disorder. *Revista de psiquiatria do Rio Grande do Sul*.  
817 2006;28(3):290-7.
- 818 55. Benczik E. Escala de avaliação dos comportamentos infantojuvenis no TDAH em  
819 ambiente familiar - Versão para pais (ETDAH-PAIS). 1st ed. Vol. 1. Memnon;  
820 2018.
- 821 56. Benczik E. Escala de Autoavaliação do TDAH-Versão para crianças e  
822 adolescentes (ETDAH-Criad). 1st ed. Vol. 1. Memnon; 2018.
- 823 57. Kamakura W, Mazzon JA. Socioeconomic Stratification Criteria and Classification  
824 Tools in Brazil. *Revista de administração de empresas*. 2016; 56:55-70.
- 825 58. Associação Brasileira de Empresas de Pesquisa (ABEP). Alterações na aplicação  
826 do Critério Brasil, válidas a partir de 16/04/2018. 2018.

- 827 59. Fernandes C. Validação do questionário de avaliação de atividade física em  
828 crianças com idade entre 9 e 10 anos. Vitória. Tese [Mestrado em Educação  
829 Física] – Universidade Federal do Espírito Santo; 2012.
- 830 60. Ministério do Desenvolvimento e Combate à fome - Secretaria de Avaliação e  
831 Gestão da Informação (MDS-SAGI). Escala brasileira de Insegurança Alimentar  
832 (EBIA): análise psicométrica de uma dimensão da Segurança Alimentar e  
833 Nutricional. Estudo técnico nº1/2014.
- 834 61. Ministério da Saúde. Orientações para avaliação de marcadores de consumo  
835 alimentar na atenção básica. 2015, access on feb 11 of 2023]. Available on  
836 [https://bvsmms.saude.gov.br/bvs/publicacoes/marcadores\\_consumo\\_alimentar\\_at](https://bvsmms.saude.gov.br/bvs/publicacoes/marcadores_consumo_alimentar_at_encao_basica.pdf)  
837 [encao\\_basica.pdf](https://bvsmms.saude.gov.br/bvs/publicacoes/marcadores_consumo_alimentar_at_encao_basica.pdf)
- 838 62. Gibson RS, Ferguson EL. An interactive 24-hour recall for assessing the adequacy  
839 of iron and zinc intakes in developing countries. Washington, DC, and California:  
840 International Food Policy Research Institute (IFPRI) and International Center for  
841 Tropical Agriculture (CIAT). 2008.
- 842 63. Gibson RS, Charrondiere UR, Bell W. Measurement errors in dietary assessment  
843 using self-reported 24-hour recalls in low-income countries and strategies for their  
844 prevention. *Advances in Nutrition*. 2017;8(6):980-991.
- 845 64. Kidscape: preventing bullying, protecting children. [Accessed on feb 11 of 2013].  
846 Available on <http://www.kidscape.org.uk/> Access on: 11/02/2023.
- 847 65. Delgado AB, Lima ML. Contribution to Concurrent Validity of Treatment  
848 Adherence. *Psicologia, Saúde e Doenças*. 2001;2(2):81-100.

- 849 66. Pereira BA de AX, Schram PFC, Azevedo RCS de. Evaluation of the Brazilian  
850 version of the CRAFFT/CESARE scale for screening drug use by adolescents.  
851 *Ciência & Saúde Coletiva*. 2016 Jan;21(1):91–9.
- 852 67. Silveira DX, Jorge MR. Psychometric properties of the epidemiologic screening  
853 scale for depression (CES-D) in clinical and non-clinical populations of adolescents  
854 and young adults. *Revista de psiquiatria clínica (São Paulo)*; 1998; 25(5):251-61.
- 855 68. Biaggio AMB, Natalício L, Spielberger CD. Desenvolvimento da forma  
856 experimental em português do Inventário de Ansiedade Traço-Estado (IDATE).  
857 Rio de Janeiro. *Arquivos brasileiros de psicologia*. 1977; 29 (3): 3144.
- 858 69. Leite WB. Avaliação das propriedades psicométricas da escala de autorrelato de  
859 sintomas do transtorno do déficit de atenção e hiperatividade ASRS-18. Belo  
860 Horizonte. Tese [Mestrado em Neurociências] - Universidade Federal de Minas  
861 Gerais. 2011.
- 862 70. Mendéz, EB. Uma versão brasileira do AUDIT (Alcohol use disorders identification  
863 test). Pelotas. Tese [Mestrado em Epidemiologia] - Universidade Federal de  
864 Pelotas. 1999.
- 865 71. Costa DS, Paula JJ de, Malloy-Diniz LF, Romano-Silva MA, Miranda DM. Parent  
866 SNAP-IV rating of attention-deficit/hyperactivity disorder: accuracy in a clinical  
867 sample of ADHD, validity, and reliability in a Brazilian sample. *Jornal de Pediatria*.  
868 2019 Nov;95(6):736–43.
- 869 72. Ferreira V. Escala de distúrbios do sono em crianças: tradução, adaptação cultural  
870 e validação. São Paulo. Tese [Mestrado em Ciências] – Universidade Federal de  
871 São Paulo - Escola Paulista de Medicina. 2009.



- 872 73. Cianchetti C, Pasculli M, Pittau A, Campus MG, Carta V, Littarru R, et al. Child and  
873 Adolescent Behavior Inventory (CABI): Standardization for age 6-17 Years and  
874 First Clinical Application. *Clinical Practice & Epidemiology in Mental Health*. 2017  
875 Mar 22;13(1):20–6.
- 876 74. Oliveira TD, Costa DS de, Albuquerque MR, Malloy-Diniz LF, Miranda DM, de  
877 Paula JJ. Cross-cultural adaptation, validity, and reliability of the Parenting Styles  
878 and Dimensions Questionnaire – Short Version (PSDQ) for use in Brazil. *Revista*  
879 *Brasileira de Psiquiatria*. 2018 Jun 11;40(4):410–9.
- 880 75. Bartholomeu D, Silva MCR da, Montiel JM. Teste de habilidades sociais para  
881 crianças e adolescentes em situação escolar (THAS-C). 1st ed. Vol. 1. Memnon;  
882 2014.
- 883 76. Pasquali L. Manual Técnico e de Aplicação do Teste Não-Verbal de Raciocínio  
884 para Crianças - TNVRI. 1st ed. Vol. 1. São Paulo - SP. Vetor editora; 2005. P.1-  
885 82.
- 886 77. Rueda FJM. BPA - Bateria psicológica para avaliação da atenção. 1st ed. Vol. 1.  
887 São Paulo - SP. Vetor editora; 2013.
- 888 78. Rueda FJM, Monteiro RM de. Psychological Battery for Attention Assessment  
889 (BPA): performance of different age groups. *Psico-USF*. 2013;18(1):99–108.
- 890 79. Sedó M, Paula JJ de, Malloy-Diniz LF. Five Digit Test. 1st ed. Vol. 1. Hogrefe;  
891 2015.
- 892 80. Salles JF de, Fonseca RP, Rodrigues CC, Mello CB, Barbosa T, Miranda MC.  
893 Development of the Child Brief Neuropsychological Assessment Battery  
894 NEUPSILIN-INF. *Psico-USF*. 2011; 16(3): 297-305.

- 895 81. Crispim SP et al. Manual fotográfico de quantificação alimentar. 2017. Curitiba:  
896 Universidade Federal do Paraná. 2017.
- 897 82. International Dietary Data Expansion Project. 24-hour Dietary Recall (24HR).  
898 [Accessed on feb 11 of 2023]. Available on  
899 [https://index.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-](https://index.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-24hr)  
900 [24hr](https://index.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-24hr)
- 901 83. Guy W. Clinical Global Impression (CGI): ECDEU Assessment Manual for  
902 Psychopharmacology. Department of Health, Education, and Welfare. 1976.
- 903 84. Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research  
904 tool in clinical practice. *Psychiatry (edgmont)*. 2007;4(7): 29-37.
- 905 85. Lima MS de et al. The Portuguese version of the Clinical Global Impression –  
906 Schizophrenia Scale: validation study. *Revista Brasileira de Psiquiatria*.  
907 2007;29(3):246-9
- 908 86. Advokat C, Scheithauer M. Attention-deficit hyperactivity disorder (ADHD)  
909 stimulant medications as cognitive enhancers. *Frontiers in Neuroscience*.  
910 2013;7(82).
- 911 87. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al.  
912 Methylphenidate for children and adolescents with attention deficit hyperactivity  
913 disorder (ADHD). *Cochrane Database of Systematic Reviews*. 2015 Nov 25.
- 914 88. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al.  
915 Comparative efficacy, and tolerability of medications for attention-deficit  
916 hyperactivity disorder in children, adolescents, and adults: a systematic review and  
917 network meta-analysis. *Lancet Psychiatry*. 2018 Sep;5(9):727-738.

- 918 89. Lin SK, Tsai SM, Huang JC, Lee SC, Wu SH, Wu SH, et al. Effects of storage time  
919 and temperature on the stability of glutathione in deproteinized blood samples.  
920 Journal of Food and Drug Analysis. 2020 Jul 14;14(2).
- 921 90. Gejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB.  
922 Associations between serum and plasma brain-derived neurotrophic factor and  
923 influence of storage time and centrifugation strategy. Scientific Reports. 2019; 9:  
924 9655.
- 925 91. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites  
926 for cytokine measurements in clinical trials with multiplex immunoassays. BMC  
927 Immunology. 2009;10(1):52.
- 928 92. Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Stability of cytokines,  
929 chemokines and soluble activation markers in unprocessed blood stored under  
930 different conditions. Cytokine. 2016 Aug; 84:17–24.
- 931 93. Gong Y, Liang S, Zeng L, Ni Y, Zhou S, Yuan X. Effects of blood sample handling  
932 procedures on measurable interleukin 6 in plasma and serum. Journal of Clinical  
933 Laboratory Analysis. 2019 May 26;33(7).
- 934 94. Chiswick EL, Duffy E, Japp B, Remick D. Detection and Quantification of Cytokines  
935 and Other Biomarkers. Methods in Molecular Biology [Internet]. 2011 Dec 21; 844:15–  
936 30.
- 937 95. Jansen EHJM, Beekhof PK, Cremers JWJM, Viezeliene D, Muzakova V, Skalicky  
938 J. Short-Term Stability of Biomarkers of Oxidative Stress and Antioxidant Status in  
939 Human Serum. ISRN Biomarkers. 2013 Jun 18; 2013:1–5.

- 940 96. Jansen EHJM, Beekhof PK, Viezeliene D, Muzakova V, Skalicky J. Long-term  
941 stability of oxidative stress biomarkers in human serum. *Free Radical Research*.  
942 2017 Nov 28;51(11-12):970–7.
- 943 97. Osterberg L, Blaschke T. Adherence to Medication. *The New England Journal of*  
944 *Medicine*. 2005; 353:487-97.
- 945 98. Cortese S et al. Candidate diagnostic biomarkers for neurodevelopmental  
946 disorders in children and adolescents: a systematic review. *World Psychiatry*.  
947 2023; 22(1): 129-149.

948

## 949 **Supporting Information**

950 S1\_File. SPIRIT Checklist.

**Fig 1. Schedule of enrolment, interventions, and assessments.**

TIMEPOINT**	STUDY PERIOD							
	Enrolment	Allocation	Post-allocation					Close-out
	$-t_1$	$t_0$	$t_1$ baseline	$t_2$ 4 sem	$t_3$ 8 sem	$t_4$ 12 sem	$t_5$ 18 sem	$t_6$ 24 sem
<b>ENROLMENT:</b>								
Eligibility screen	X							
K-Sads-PL	X							
Sociodemographic data	X							
Allocation		X						
<b>INTERVENTIONS:</b>								
<b>Child Questionnaires</b>								
ADHD Self-Assessment Scale – Version for Children and Adolescents (ETDAH-Cri Ad)			X			X		X
ADHD Behavior Assessment Scale - Parental Version (ETDAH-parents)			X			X		X
SNAP-IV			X			X		X
Psychiatry interview (standard record)			X	X	X	X	X	X
Physical Examination			X	X	X	X	X	X
Measure Treatment Adherence (MTA) and pill count			X	X	X	X	X	X
24-hour food recall			X			X		X
SISVAN food consumption markers			X			X		X
Bullying questionnaire (Kidscape)			X			X		X
Physical activity questionnaire			X			X		X

medRxiv preprint doi: <https://doi.org/10.1101/2023.03.03.23286780>; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Scale of sleep disorders in children			X			X		X
Social Skills Test for Children and Adolescents in School Situation (THAS-C)			X			X		X
CRAFFT/CESARE (scale for screening drug use)			X			X		X
CABI (Behavior Inventory for Children and Adolescents)			X			X		X
<b>Caregivers Questionnaires</b>								
Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ)			X			X		X
Brazilian Food Security Scale (EBIA)			X			X		X
Epidemiological Studies Center Depression Scale (CES-D)			X			X		X
State-Trait Anxiety Inventory (IDATE)			X			X		X
Audit (Alcohol Use Disorder Identification Test)			X			X		X
Asr18 (Adult Self-Report Scale)			X			X		X
<b>Neuropsychological Assessment</b>								
TNVRI			X			X		X
BPA			X			X		X
FDT			X			X		X
Neupsilin			X					
<b>Pharmacological Intervention</b>								
Methylphenidate (short acting)			X	X	X	X	X	X
<b>Sample Blood</b>								
BDNF			X			X		X
Cytokines			X			X		X
Oxidative stress			X			X		X
<b>ASSESSMENTS:</b>								


medRxiv preprint doi: <https://doi.org/10.1101/2023.03.03.23286780>; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

<b><i>First trial assessment</i></b>			X					
<b><i>Second trial assessment</i></b>						X		
<b><i>Third trial assessment</i></b>								X

medRxiv preprint doi: <https://doi.org/10.1101/2023.03.03.23286780>; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).



Fig. 2. The participants visit.



\* Assessment points (Psychiatric clinical follow-up, Nutrition assessment, Neuropsychological assessment, Sample Blood, Questionnaires and Scales)

\*\* Methylphenidate prescription after first blood sample.

\*\*\*Children who finished the trial times will be transferred to the general outpatient clinic of child psychiatry at the UFV medical school.